Notice: This company has been marked as potentially delisted and may not be actively trading. Positive News SentimentPositive NewsNASDAQ:INTS Intensity Therapeutics, Inc. Common stock (INTS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesOwnershipShort InterestTrends About Intensity Therapeutics, Inc. Common stock Stock (NASDAQ:INTS) 30 days 90 days 365 days Advanced Chart Remove Ads Get INTS alerts:Sign Up Key Stats Today's Range$2.36▼$2.7950-Day Range N/A52-Week Range$1.50▼$5.78Volume73,559 shsAverage Volume21,289 shsMarket Capitalization$34.53 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingBuy Company OverviewIntensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.Read More… Remove Ads Intensity Therapeutics, Inc. Common stock Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreINTS MarketRank™: Intensity Therapeutics, Inc. Common stock scored higher than 47% of companies evaluated by MarketBeat, and ranked 654th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingIntensity Therapeutics, Inc. Common stock has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIntensity Therapeutics, Inc. Common stock has only been the subject of 1 research reports in the past 90 days.Read more about Intensity Therapeutics, Inc. Common stock's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Intensity Therapeutics, Inc. Common stock are expected to grow in the coming year, from ($1.18) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intensity Therapeutics, Inc. Common stock is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intensity Therapeutics, Inc. Common stock is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntensity Therapeutics, Inc. Common stock has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.61% of the float of Intensity Therapeutics, Inc. Common stock has been sold short.Short Interest Ratio / Days to CoverIntensity Therapeutics, Inc. Common stock has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intensity Therapeutics, Inc. Common stock has recently decreased by 3.11%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntensity Therapeutics, Inc. Common stock does not currently pay a dividend.Dividend GrowthIntensity Therapeutics, Inc. Common stock does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.61% of the float of Intensity Therapeutics, Inc. Common stock has been sold short.Short Interest Ratio / Days to CoverIntensity Therapeutics, Inc. Common stock has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intensity Therapeutics, Inc. Common stock has recently decreased by 3.11%, indicating that investor sentiment is improving. News and Social Media1.1 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Intensity Therapeutics, Inc. Common stock this week, compared to 0 articles on an average week.Search Interest17 people have searched for INTS on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Intensity Therapeutics, Inc. Common stock insiders have not sold or bought any company stock.Percentage Held by Insiders18.60% of the stock of Intensity Therapeutics, Inc. Common stock is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.74% of the stock of Intensity Therapeutics, Inc. Common stock is held by institutions.Read more about Intensity Therapeutics, Inc. Common stock's insider trading history. Receive INTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intensity Therapeutics, Inc. Common stock and its competitors with MarketBeat's FREE daily newsletter. Email Address INTS Stock News HeadlinesIntensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate UpdateMarch 13 at 4:07 PM | prnewswire.comDrug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic ReviewJanuary 28, 2025 | prnewswire.comPlease don’t die on me"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.March 13, 2025 | Porter & Company (Ad)Alliance Global Partners Initiates Coverage of Intensity Therapeutics (INTS) with Buy RecommendationJanuary 14, 2025 | msn.comIntensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6January 10, 2025 | prnewswire.comIntensity Therapeutics files to sell 1.24M shares of common stock for holdersDecember 14, 2024 | markets.businessinsider.comIntensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)December 12, 2024 | prnewswire.comPromising Clinical Progress and Financial Stability Drive Positive Outlook for Intensity Therapeutics, Inc.November 22, 2024 | markets.businessinsider.comSee More Headlines INTS Stock Analysis - Frequently Asked Questions How were Intensity Therapeutics, Inc. Common stock's earnings last quarter? Intensity Therapeutics, Inc. Common stock (NASDAQ:INTS) issued its quarterly earnings data on Friday, August, 9th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.04. When did Intensity Therapeutics, Inc. Common stock IPO? Intensity Therapeutics, Inc. Common stock (INTS) raised $20 million in an initial public offering on Friday, June 30th 2023. The company issued 3,900,000 shares at $5.00 per share. Who are Intensity Therapeutics, Inc. Common stock's major shareholders? Intensity Therapeutics, Inc. Common stock's top institutional shareholders include Sapient Capital LLC (6.24%), Sigma Planning Corp (0.36%), Mesirow Financial Investment Management Inc. (0.13%) and GTS Securities LLC (0.13%). What other stocks do shareholders of Intensity Therapeutics, Inc. Common stock own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intensity Therapeutics, Inc. Common stock investors own include Amgen (AMGN), Costco Wholesale (COST), Cisco Systems (CSCO), Honeywell International (HON), Intel (INTC), Intuitive Surgical (ISRG) and Mondelez International (MDLZ). Company Calendar Last Earnings8/09/2024Today3/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:INTS CIK1567264 Webwww.intensitytherapeutics.com Phone203 221 7381FaxN/AEmployees2,021Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$12.00 Low Stock Price Target$5.00 Potential Upside/Downside+268.0%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-209.73% Return on Assets-149.19% Debt Debt-to-Equity Ratio0.04 Current Ratio1.63 Quick Ratio1.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.96 per share Price / Book2.41Miscellaneous Outstanding Shares15,100,000Free Float12,295,000Market Cap$34.88 million OptionableNot Optionable Beta4.03 10 Best Stocks to Own in 2025Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:INTS) was last updated on 3/13/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intensity Therapeutics, Inc. Common stock Please log in to your account or sign up in order to add this asset to your watchlist. Share Intensity Therapeutics, Inc. Common stock With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
